Sanofi Performance degli utili passati
Criteri Il passato verificati 0/6
Gli utili di Sanofi sono diminuiti a un tasso medio annuo di -9.5%, mentre il settore Pharmaceuticals ha visto gli utili diminuire a un tasso medio annuo di 5.7%. I ricavi sono cresciuti crescere a un tasso medio annuo di 4.1%. Il ritorno sul capitale proprio di Sanofi è 6.6% e ha margini netti di 10.2%.
Informazioni chiave
-9.47%
Tasso di crescita degli utili
-9.08%
Tasso di crescita dell'EPS
| Pharmaceuticals Crescita del settore | 16.27% |
| Tasso di crescita dei ricavi | 4.10% |
| Rendimento del capitale proprio | 6.63% |
| Margine netto | 10.20% |
| Prossimo aggiornamento sugli utili | 30 Jul 2026 |
Aggiornamenti sulle prestazioni recenti
Articolo di analisi • May 04
Sanofi's (EPA:SAN) Conservative Accounting Might Explain Soft Earnings
Shareholders appeared unconcerned with Sanofi's ( EPA:SAN ) lackluster earnings report last week. We think that the...Articolo di analisi • Oct 31
We Think Sanofi's (EPA:SAN) Healthy Earnings Might Be Conservative
Sanofi's ( EPA:SAN ) recent earnings report didn't offer any surprises, with the shares unchanged over the last week...Recent updates
Aggiornamento narrativa • Jul 22
SAN: New Drug Approvals And AI Discovery Partnership Will Support Future Upside
Sanofi's updated analyst price target has shifted from €112.00 to €107.20, reflecting revised assumptions around discount rates, revenue growth, profit margins and future P/E. Analysts view these changes as better aligning the stock's valuation with current fundamentals.
Aggiornamento narrativa • Jul 02
SAN: Pipeline Approvals And R&D Execution Will Shape Future Share Support
Analysts have lifted the indicative fair value for Sanofi to €82.00 from €72.40, citing updated assumptions for revenue growth, profit margins and future P/E that are broadly in line with recent upward revisions to price targets seen across parts of the European market. Analyst Commentary Analysts covering Sanofi have framed the updated fair value in the context of broader reassessments across European equities, with the new €82.00 level positioned as an attempt to reflect current assumptions on growth, profitability and P/E multiples rather than a shift driven by any single catalyst.
Aggiornamento narrativa • Jun 18
SAN: Future Upside Will Hinge On AI Execution Across R&D Workflows
Sanofi's analyst price target has been revised slightly to €96.70 from €97.10. This change reflects updated views on its revenue growth outlook, profit margin assumptions and a modestly adjusted future P/E multiple, according to recent analyst commentary.Aggiornamento narrativa • Jun 04
SAN: Future Upside Will Depend On AI Execution And R&D Pipeline Delivery
Analysts have nudged their fair value estimate for Sanofi higher from €95.53 to €97.10, citing slightly adjusted assumptions on discount rate, revenue growth, profit margins and future P/E as the basis for the updated price target. Analyst Commentary Bullish analysts framing the updated fair value for Sanofi around €97.10 are effectively signaling confidence that the company can execute in line with, or slightly ahead of, their refined assumptions on discount rate, revenue trajectory, margins and implied future P/E.Articolo di analisi • May 04
Sanofi's (EPA:SAN) Conservative Accounting Might Explain Soft Earnings
Shareholders appeared unconcerned with Sanofi's ( EPA:SAN ) lackluster earnings report last week. We think that the...Aggiornamento narrativa • Apr 22
SAN: Future Upside Will Rely On Pipeline Delivery And Margin Execution
Sanofi's analyst price target has been adjusted slightly lower to €95.53 from €96.10, as analysts factor in marginally higher revenue growth expectations, a modestly lower profit margin and a revised forward P/E assumption. Analyst Commentary Recent Street research on large European financials and cross border bank transactions offers a useful lens for thinking about how analysts might be framing Sanofi's current valuation reset and execution risks, even though the specific notes focus on banks rather than pharmaceuticals.Nuova narrativa • Apr 14
Pipeline And Vaccine Catalysts Will Reshape This Pharma Leader Over The Next Decade
Catalysts About Sanofi Sanofi is a global biopharma group focused on prescription medicines, vaccines and specialty care therapies. What are the underlying business or industry changes driving this perspective?Aggiornamento narrativa • Apr 07
SAN: Future Upside Will Rely On Pipeline Delivery And Margin Expansion
Analysts trimmed Sanofi's fair value estimate by €2.00 to €96.10, citing updated assumptions that include slightly different revenue growth, a higher profit margin profile, and a lower future P/E multiple. Analyst Commentary Recent Street research on European financials and cross border bank deals offers some reference points that investors can use when thinking about Sanofi's updated fair value and how sentiment can swing as assumptions change.Nuova narrativa • Mar 31
Rising R&D Burden And Pipeline Risk Will Challenge Long Term Profitability
Catalysts About Sanofi Sanofi is a global biopharmaceutical company focused on prescription medicines, vaccines and specialty care therapies. What are the underlying business or industry changes driving this perspective?Aggiornamento narrativa • Mar 24
SAN: Future Upside Will Rely On Pipeline Execution And Margin Strength
Sanofi's analyst price target has been adjusted to €98.10 from €98.49 as analysts factor in slightly higher assumed revenue growth, stronger profit margins and a lower future P/E multiple in their updated models. Analyst Commentary Analysts updating their models for Sanofi are weighing the slightly higher revenue assumptions and stronger margin profile against a more conservative future P/E multiple.Aggiornamento narrativa • Mar 09
SAN: Future Upside Will Rely On Pipeline Execution And Margin Resilience
Analysts have nudged their price target on Sanofi higher to €98.49, reflecting slightly firmer revenue growth assumptions and a nearly unchanged long-term profit margin and P/E outlook. Analyst Commentary Analysts covering Sanofi are broadly focused on how the updated €98.49 price target lines up with the company’s ability to execute on its plan, sustain its profit profile and justify its current P/E.Aggiornamento narrativa • Feb 23
SAN: Future Upside Will Rely On Pipeline Delivery And Margin Stability
Analysts have trimmed their Sanofi price target slightly to €98.49. The change is tied to more cautious assumptions for revenue growth, profit margins and a modestly higher future P/E multiple.Aggiornamento narrativa • Feb 09
SAN: Future Upside Will Depend On Pipeline Execution And Margin Resilience
Analysts have trimmed their Sanofi price targets slightly, with fair value moving from about €101 to about €99 as they factor in a modestly higher discount rate, slightly softer revenue growth assumptions around 3.6% and a marginally lower expected profit margin near 19.7%, paired with a future P/E closer to 12.8x. Analyst Commentary Recent updates to Sanofi valuation assumptions, including a modestly higher discount rate and slightly softer revenue and margin expectations, have led analysts to fine tune their views rather than overhaul them.Aggiornamento narrativa • Jan 25
SAN: Future Upside Will Depend On Pipeline Approvals And Margin Discipline
Analysts have trimmed their price target on Sanofi to reflect a fair value move from €102.77 to €100.96, citing updated assumptions around revenue growth, profit margins and future P/E levels. Analyst Commentary While the latest fair value trim for Sanofi is modest, it still reflects a tight range of outcomes that analysts see as reasonable based on current assumptions around growth, profitability and P/E levels.Aggiornamento narrativa • Jan 11
SAN: Future Upside Will Depend On Pipeline Approvals And Margin Discipline
Analysts have trimmed their fair value estimate for Sanofi from about €104.87 to roughly €102.77, pointing to slightly softer assumptions for revenue growth, profit margins and future P/E as key drivers of the updated price target outlook. Analyst Commentary Recent fair value adjustments for Sanofi sit against a backdrop of active price target revisions across European equities, including large financials, where several research desks have been updating their expectations.Aggiornamento narrativa • Dec 25
SAN: Future Upside Will Depend On Pipeline Delivery And Cost Discipline
Analysts have trimmed their price target for Sanofi modestly, cutting their fair value estimate by about EUR 0.33 to roughly EUR 104.87. They cite slightly slower revenue growth, a softer profit margin profile, and a marginally higher future earnings multiple as the main factors behind this adjustment.Aggiornamento narrativa • Dec 11
SAN: Future Returns Will Depend On Execution Of Late-Stage Pipeline
Analysts have nudged their fair value estimate for Sanofi slightly lower from EUR 106.26 to about EUR 105.20, citing marginally softer revenue growth assumptions, partially offset by a modestly stronger profit margin outlook and a slightly reduced forward P E multiple. Analyst Commentary Analyst sentiment on Sanofi remains broadly constructive, with recent fair value adjustments reflecting a more nuanced balance between growth ambitions and execution risks.Aggiornamento narrativa • Nov 27
SAN: Future Momentum Will Depend On Execution Of New Pipeline Approvals
Sanofi's analyst price target has been modestly adjusted downward from $106.85 to $106.26. Analysts point to slight improvements in profit margin and future valuation metrics while maintaining a broadly stable outlook.Aggiornamento narrativa • Nov 10
SAN: Forward Momentum Will Rely On Pipeline Success And Operational Execution
Sanofi's analyst price target saw a slight decrease to $106.85 from $106.90. Analysts cite moderating revenue growth expectations and a slightly higher discount rate impacting the updated valuation.Articolo di analisi • Oct 31
We Think Sanofi's (EPA:SAN) Healthy Earnings Might Be Conservative
Sanofi's ( EPA:SAN ) recent earnings report didn't offer any surprises, with the shares unchanged over the last week...Aggiornamento narrativa • Oct 27
Future Shareholder Returns Will Depend On Commercial Execution And Pipeline Momentum
Sanofi's analyst price target has been slightly lowered from €108.31 to €106.90. Analysts cite modest improvements in revenue growth and profit margin, but note a more conservative outlook for the company's future valuation.Ripartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come Sanofi guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Mar 26 | 47,354 | 4,829 | 9,721 | 7,781 |
| 31 Dec 25 | 46,716 | 4,939 | 9,616 | 7,842 |
| 30 Sep 25 | 45,931 | 6,430 | 9,509 | 7,808 |
| 30 Jun 25 | 45,738 | 6,383 | 9,448 | 7,776 |
| 31 Mar 25 | 45,166 | 6,218 | 9,358 | 7,532 |
| 31 Dec 24 | 44,286 | 5,496 | 9,247 | 7,394 |
| 30 Sep 24 | 48,445 | 4,506 | 10,945 | 7,147 |
| 30 Jun 24 | 39,547 | 3,676 | 8,122 | 6,649 |
| 31 Mar 24 | 46,288 | 4,538 | 10,763 | 6,884 |
| 31 Dec 23 | 41,109 | 5,062 | 9,003 | 6,507 |
| 30 Sep 23 | 45,699 | 9,066 | 10,703 | 6,679 |
| 30 Jun 23 | 46,045 | 8,617 | 10,783 | 6,752 |
| 31 Mar 23 | 46,199 | 8,357 | 10,767 | 6,780 |
| 31 Dec 22 | 40,304 | 7,970 | 8,785 | 6,501 |
| 30 Sep 22 | 44,348 | 6,409 | 10,399 | 6,468 |
| 30 Jun 22 | 42,039 | 6,643 | 10,025 | 6,176 |
| 31 Mar 22 | 40,342 | 6,666 | 9,784 | 5,914 |
| 31 Dec 21 | 39,175 | 6,223 | 9,599 | 5,692 |
| 30 Sep 21 | 38,496 | 6,174 | 9,457 | 5,622 |
| 30 Jun 21 | 37,546 | 5,777 | 9,362 | 5,501 |
| 31 Mar 21 | 36,939 | 12,197 | 9,301 | 5,455 |
| 31 Dec 20 | 37,369 | 12,294 | 9,448 | 5,530 |
| 30 Sep 20 | 37,650 | 11,224 | 9,613 | 5,699 |
| 30 Jun 20 | 37,692 | 11,138 | 9,729 | 5,738 |
| 31 Mar 20 | 38,234 | 3,453 | 9,936 | 5,973 |
| 31 Dec 19 | 37,631 | 2,855 | 9,967 | 6,020 |
| 30 Sep 19 | 36,940 | 3,179 | 9,951 | 6,010 |
| 30 Jun 19 | 36,763 | 3,591 | 9,959 | 6,111 |
| 31 Mar 19 | 36,264 | 4,439 | 9,998 | 5,999 |
| 31 Dec 18 | 35,677 | 4,319 | 9,934 | 5,894 |
| 30 Sep 18 | 35,316 | 4,041 | 9,906 | 5,680 |
| 30 Jun 18 | 34,985 | 3,243 | 9,918 | 5,560 |
| 31 Mar 18 | 35,428 | 3,539 | 9,980 | 5,443 |
| 31 Dec 17 | 36,221 | 3,773 | 10,164 | 5,472 |
| 30 Sep 17 | 36,400 | 4,593 | 10,077 | 5,445 |
| 30 Jun 17 | 36,315 | 4,744 | 10,034 | 5,325 |
| 31 Mar 17 | 35,677 | 4,682 | 9,866 | 5,246 |
| 31 Dec 16 | 34,696 | 4,395 | 9,592 | 5,172 |
| 30 Sep 16 | 34,349 | 4,195 | 9,479 | 5,099 |
| 30 Jun 16 | 34,115 | 4,154 | 9,452 | 5,191 |
| 31 Mar 16 | 34,569 | 4,440 | 9,458 | 5,158 |
| 31 Dec 15 | 34,861 | 4,411 | 9,496 | 5,082 |
| 30 Sep 15 | 37,201 | 5,292 | 10,154 | 5,195 |
Guadagni di qualità: SAN ha un grande una tantum perdita di €3.6B che ha avuto un impatto sui suoi ultimi 12 mesi di risultati finanziari pari a 31st March, 2026.
Margine di profitto in crescita: Gli attuali margini di profitto netti di SAN (10.2%) sono inferiori rispetto allo scorso anno (13.8%).
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: Gli utili di SAN sono diminuiti del 9.5% all'anno negli ultimi 5 anni.
Accelerare la crescita: SAN ha avuto una crescita negativa degli utili nell'ultimo anno, quindi non può essere confrontata con la sua media quinquennale.
Guadagni vs Settore: SAN ha avuto una crescita negativa degli utili ( -22.3% ) nell'ultimo anno, rendendo difficile il confronto con la media del settore Pharmaceuticals ( 3.9% ).
Rendimento del capitale proprio
ROE elevato: Il Return on Equity ( 6.6% ) di SAN è considerato basso.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/27 05:20 |
| Prezzo dell'azione a fine giornata | 2026/07/27 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Sanofi è coperta da 51 analisti. 20 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| John Eade | Argus Research Company |
| Odile Rundquist | Baader Helvea Equity Research |
| null null | Banco de Sabadell. S.A. |